Supplements and Featured Publications
- Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran
Participating Faculty: Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran
Faculty
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
University of Michigan
Ann Arbor, MI
Faculty Disclosures
The following have relevant commercial financial relationships or affiliations to disclose:
Steven W. Pipe, MD, reports the following relevant commercial financial relationships or affiliations in the past 12 months:
CONSULTANCIES OR PAID ADVISORY BOARDS
Bayer, BioMarin, Chugai, CSL Behring, HEMA Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Roche/Genentech/Spark Therapeutics, Sanofi, Star Therapeutics, and Takeda
LECTURE FEES AT THE INVITATION OF A COMMERCIAL SPONSOR
Chugai, Roche, Sanofi
MEETING/CONFERENCE ATTENDANCE
Sanofi
SCIENTIFIC ADVISORY BOARDS
Equilibra, GeneVentiv
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
























































